Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
NCT00045786
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndrome
Interventions
DRUG:
CC-1088
Sponsor
Celgene